Dr. Sue Kim is a globally recognized expert in stem cell and exosome research, with over 25 years of experience spanning both academia and industry. She currently serves as the CEO and CSO of Brexogen Inc., a biotechnology company at the forefront of developing next-generation, cell-free regenerative therapeutics.

Dr. Kim earned her Ph.D. from Seoul National University and has since held senior research and leadership positions in biotechnology and prominent medical institutions, including Asan Medical Center and the University of Illinois at Chicago.

Her research focuses on the development of exosome therapeutics powered by BG-Platform technology, targeting a range of indications including autoimmune skin disorders and other chronic diseases. With deep expertise in clinical and translational research, she is currently leading global clinical trials for exosome-based therapeutics.

Beyond pharmaceutical applications, Dr. Kim has spearheaded the development of exosomes designed to modulate various skin environments, resulting in the launch of BREXTEM, an aesthetic medicine solution that has demonstrated strong clinical efficacy. She has also cargo-tailored primed exosomes enriched with key rejuvenating factors for aging skin, laying the groundwork for best-in-class exosome-based solutions in both aesthetic dermatology and the broader anti-aging therapeutics market.